© AlphaMed Press 2015. Biliary tract cancers (BTCs) encompass a group of invasive carcinomas, including cholangiocarcinoma (intrahepatic, perihilar, orextrahepatic), andgallbladder carcinoma.Approximately90% of patients present with advanced, unresectable disease and have a poor prognosis. The latest recommendation is to treat advanced ormetastatic disease with gemcitabine and cisplatin, although chemotherapy has recordedmodest survival benefits. Comprehension of the molecular basis of biliary carcinogenesis has resulted in experimental trials of targeted therapies in BTCs, with promising results.This review addresses the emerging role of targeted therapy in the treatment of BTCs. Findings from preclinical studies were reviewed and correlated with the outcomes of clinical trials thatwere undertaken to translate the laboratory discoveries.
CITATION STYLE
Oyasiji, T., Zhang, J., Kuvshinoff, B., Iyer, R., & Hochwald, S. N. (2015). Molecular Targets in Biliary Carcinogenesis and Implications for Therapy. The Oncologist, 20(7), 742–751. https://doi.org/10.1634/theoncologist.2014-0442
Mendeley helps you to discover research relevant for your work.